Esophagitis dissecans superficialis with immune checkpoint inhibitor therapy

Esophagitis dissecans superficialis with immune checkpoint inhibitor therapy

Immune checkpoint inhibitors represent an important advance in cancer treatment, but immune mediated adverse events associated with their use can be severe and life-threatening. Esophagitis dissecans superficialis, a rare condition of the esophagus characterized by diffuse desquamation and sloughing...

Full description

Bibliographic Details
Main Authors:	Alexis Coolidge, Nicolette Juliana Rodriguez, Mark Pomerantz, Shilpa Grover
Format:	Article
Language:	English
Published:	Elsevier 2021-03-01
Series:	Current Problems in Cancer: Case Reports
Subjects:	Esophagitis dissecans superficialis Immune checkpoint inhibitor toxicity Esophagogastroduodenoscopy Immune related adverse events
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666621920300442

Similar Items

Esophagitis Dissecans Superficialis (EDS) Secondary to Hair Dye Ingestion: Case Report and Literature Review
by: Eric Omar Then, et al.
Published: (2021-03-01)

Ferrous Sulfate-Induced Esophageal Injury Leading to Esophagitis Dissecans Superficialis
by: Umair M. Nasir, et al.
Published: (2020-04-01)

Checkpoint inhibitor induced esophagitis with documented resolution on infliximab
by: Frank W. Chen, et al.
Published: (2020-12-01)

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
by: Marina A. Lyadova, et al.
Published: (2021-08-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
by: I. Puzanov, et al.
Published: (2017-11-01)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01)

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
by: J. Randall Patrinely, et al.
Published: (2021-01-01)

Overview and management of toxicities of immune checkpoint-blocking drugs
by: Economopoulou Panagiota, et al.
Published: (2016-03-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients
by: Johnny Chahine, MD, et al.
Published: (2020-02-01)

IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)

Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors
by: Nicholas Gulati, et al.
Published: (2020-11-01)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
by: Junling Zhuang, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events
by: Junling ZHUANG, et al.
Published: (2019-10-01)

Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor
by: Marta Rocha, et al.
Published: (2018-12-01)

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database
by: Quentin Scanvion, et al.
Published: (2020-01-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
by: Xiaowei Liu, et al.
Published: (2020-03-01)

Graves’ Disease During Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
by: Mathilde Peiffert, et al.
Published: (2021-04-01)

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01)

Management of immune-related adverse events in patients treated with immune checkpoint inhibitors– Rheumatology point of view
by: Ho Cheuk Man, et al.
Published: (2018-12-01)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
by: Katarina Hradska, et al.
Published: (2021-08-01)

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors
by: ZHANG Xue, et al.
Published: (2020-11-01)

Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction
by: Lian Duan, et al.
Published: (2020-04-01)

Immune Checkpoint Inhibitor-Induced Gastroduodenitis: Recurrence after Rechallenge with Pembrolizumab
by: Catarina O’Neill, et al.
Published: (2021-04-01)

Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms
by: Rishi Rikhi, et al.
Published: (2021-08-01)

Estudio de la vascularización arterial del músculo flexor digitorum superficialis Anatomical study of the arterial vascularization of the flexor digitorum superficialis muscle
by: N. Comellas Melero, et al.
Published: (2010-03-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
by: Hanping Wang, et al.
Published: (2020-01-01)

Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
by: Anca Bobircă, et al.
Published: (2021-06-01)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
by: Roser Calvo
Published: (2019-04-01)

Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Jiaxin ZHOU, et al.
Published: (2019-10-01)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
by: Jiaxin Zhou, et al.
Published: (2020-01-01)

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
by: Alice Horisberger, et al.
Published: (2018-12-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events of Edocrine System Related to Immune Checkpoint Inhibitors
by: Lian DUAN, et al.
Published: (2019-10-01)

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy
by: Terufumi Kubo, et al.
Published: (2021-09-01)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
by: Peng Song, et al.
Published: (2020-08-01)

Immune Checkpoint Inhibitors and the Heart
by: Diana Larisa Mocan-Hognogi, et al.
Published: (2021-09-01)

A case of checkpoint inhibitor-induced celiac disease
by: Dana Alsaadi, et al.
Published: (2019-08-01)

Cannot write session to /tmp/vufind_sessions/sess_6e1ue3ererkgm8l3thteo7ev8s